Skip to main content

The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2025 in Germany, has been set at 4.41%. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.

The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2025 in Germany, has been set at 4.41%. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.

November 19

November 19, 2024
Frankfurt, Germany

DZ Bank Equity Conference

Fresenius continues streamlining the production network of its Operating Company Fresenius Kabi in line with its Vision 2026 and #FutureFresenius: Today, Fresenius Kabi transferred the ownership of its subsidiary Laboratorio Sanderson S.A., Chile, to Medifarma, a multinational pharmaceutical company from Peru with a strong presence in Latin America. This divestment includes the IV Laboratorio Sanderson plant in Santiago de Chile. Medifarma will continue the manufacturing of the existing portfolio of products in Chile. Fresenius Kabi remains committed to the Chilean as well as South American markets and will continue its presence accordingly. This is another step to reduce complexity and optimize utilization in Fresenius Kabi’s global manufacturing network.

Fresenius continues streamlining the production network of its Operating Company Fresenius Kabi in line with its Vision 2026 and #FutureFresenius: Today, Fresenius Kabi transferred the ownership of its subsidiary Laboratorio Sanderson S.A., Chile, to Medifarma, a multinational pharmaceutical company from Peru with a strong presence in Latin America. This divestment includes the IV Laboratorio Sanderson plant in Santiago de Chile. Medifarma will continue the manufacturing of the existing portfolio of products in Chile. Fresenius Kabi remains committed to the Chilean as well as South American markets and will continue its presence accordingly. This is another step to reduce complexity and optimize utilization in Fresenius Kabi’s global manufacturing network.

Fresenius Kabi today announced the launch of Cetrorelix Acetate for Injection Kit, an FDA-approved, cost-effective, generic option for women’s health. Cetrorelix Acetate for Injection is a therapeutic equivalent to EMD Serono’s Cetrotide®.

With this new generic, Fresenius Kabi underscores its commitment to providing a comprehensive range of cost-effective treatment options in the field of women’s health, helping to support their options in the U.S. 

For more information, please see the website of Fresenius Kabi.
 

Fresenius Kabi today announced the launch of Cetrorelix Acetate for Injection Kit, an FDA-approved, cost-effective, generic option for women’s health. Cetrorelix Acetate for Injection is a therapeutic equivalent to EMD Serono’s Cetrotide®.

With this new generic, Fresenius Kabi underscores its commitment to providing a comprehensive range of cost-effective treatment options in the field of women’s health, helping to support their options in the U.S. 

For more information, please see the website of Fresenius Kabi.
 

Birgit Gugath
M: +49 173 28 12 169
presse@helios-gesundheit.de

  • Best practice for pooling medical expertise
  • Germany-wide centers of excellence for complex treatments
  • Clear focus on the quality of medical outcomes and patient satisfaction

The hospital system of the future already exists today: On Tuesday, the German Federal Minister of Health Prof. Dr. Karl Lauterbach and the Parliamentary State Secretary for East Germany and Minister of State Carsten Schneider visited the Helios Hospital Erfurt. Together with three other Helios hospitals, it forms part of the Central Thuringia Helios cluster. Accompanied by Robert Möller, who is the CEO of Helios and a Fresenius Management Board member, the health minister learned about the networking between Helios hospitals and the specialization based on the cluster principle. The minister also took the opportunity to speak directly with employees.

Helios sets focus areas for its clusters comprising several closely linked hospitals that it has set up all across Germany. These clusters enable the provision of a very broad range of medical services, which in turn leads to a measurably higher quality of treatment for patients.

Prof. Dr. Karl Lauterbach, German Federal Minister of Health: “All those who work together in a hospital network, specialize, and allocate tasks sensibly like the Helios Hospital Erfurt and its partner hospitals do stand to benefit from the hospital reform. Not everyone has to do everything. But anyone who carries out complex procedures must be qualified to do so. Cutting-edge medicine must pay off. Nationwide coverage must continue to be guaranteed. We will ensure just this with the reform.”

Robert Möller, member of the Fresenius Management Board and CEO of Helios: “As a healthcare provider and part of the globally active Fresenius healthcare group, Helios welcomes many of the approaches foreseen in the hospital reform, especially the efforts to establish focus areas and centers of excellence. Like the one here at Helios in Thuringia. One thing is clear though: Our focus here in Germany must be on the quality of medical outcomes and patient satisfaction. To achieve this, we must concentrate treatment in the places with the most expertise and think beyond sector boundaries. At Helios, we have consistently pursued this approach for a long time now. Always with the aim of achieving the best possible medical quality, which is also measurable. The Central Thuringia cluster of Helios hospitals is a very good example of how we are putting this into practice in many regions in Germany.”

Medical care within the cluster

As a maximum care provider, the Helios Hospital Erfurt is the largest hospital in the region. It forms the core of the Central Thuringia Helios cluster. Together with three other Helios hospitals in the surrounding area, namely the specialist orthopedic clinic in Bleicherode, the hospital for specialized care in Gotha, and the hospital for basic and standard care in Blankenhain, the cluster is an example of specialization and networking in the hospital sector. Around 300,000 people are treated within the cluster every year. The specialized medical care is provided by over 3,500 employees. Helios already has 25 strong clusters. Within these, complex treatments are pooled at centers of excellence and cross-site medical departments are formed.

Insights into daily practice

The practical work at the hospitals in the Central Thuringia Helios cluster was presented to the delegation and the close networking between sites and the specialization through the establishment of centers for different specialist areas and disciplines were also demonstrated. During his tour, the health minister experienced telemedical cooperation in a live case discussion and training for complex emergencies and in the use of state-of-the-art robotics for knee surgery in the simulation and emergency academy. The medical training program offered in Erfurt was also presented. Helios Hospital Erfurt has been a university campus of the Health and Medical University since 2022 and plays a key role in the medical training offered in Erfurt. The health minister also expressed his particular appreciation for the staff from various disciplines during personal discussions.
 

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Subscribe to